Adverse effects of immunotherapeutics involving the immune system

Toxicology

Volumn 174, Issue 1, 2002, Pages 3-11

  Vial, T ^a   Choquet Kastylevsky, G ^a,b   Descotes, J ^a,b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Adverse effects; Immunotherapeutics; Immunotoxicology

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; BETA INTERFERON; COLONY STIMULATING FACTOR RECEPTOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; METHOTREXATE; MONOCLONAL ANTIBODY; OKT 3; TACROLIMUS; VACCINE;

ALLERGY; ARTICLE; AUTOIMMUNITY; CANCER RISK; CANCER SUSCEPTIBILITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MEGADOSE; GENE THERAPY; GRAFT REJECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTOXICITY; INFECTION; INFECTION RATE; INFECTION RISK; LONG TERM EXPOSURE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN DISEASE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS;

ANIMALIA;

EID: 0037093601     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(02)00051-3     Document Type: Article

References (44)

1. Human antibodies to recombinant interleukin-2 in patients with hypernephroma
2. Posttransplant development of lymphoproliferative disroders and other malignancies following orthoclone OKT3 therapy
3. Infections during low-dose methotrexate treatment in rheumatoid arthritis
4. Adverses consequences of chemical immunomodulation
5. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
6. The optimal use of cyclosporin A in autoimmune diseases
7. Hypersensitivity reaction to azathioprine
8. Lymphoma in patients with rheumatoid arthritis: Association with the disease state or methotrexate treatment
9. De novo cancer in cyclosporin-treated and non-cyclosporin-treated adult primary renal allograft recipients
10. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression
11. Malignancy after renal transplantation: Analysis of incidence and risk factors in 1700 patients followed during a 25-year period
12. Infectious complications of cyclophosphamide treatment for vasculitis
13. Wegener granulomatosis: An analysis of 158 patients
14. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study
15. Does methotrexate increase the risk of infection or malignancy
16. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
17. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease
18. Azathioprine hypersensitivity-like reactions - A case report and a review of the literature
19. Antibodies to interferon-α in treated cancer patients: Incidence and significance
20. Intravenous and oral cyclophosphamide pulse therapy in rheumatic diseases: Side effects and complications
21. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis
22. Tumors after renal and cardiac transplantation
23. Effect of OKT3 in steroid-resistant renal transplant rejection
24. Infectious complications associated with interleukin-2 administration: A retrospective review of 935 treatment courses
25. Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia
26. Autoimmunity and thyroid dysfunction in patients with chronic active hepatitis treated with recombinant interferon alpha-2a
27. Causes of death in renal transplant recipients: A study of 102 autopsies from 1968 to 1991
28. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: Bibliographic review
29. Adverse reactions to intravenous contrast media in patients treated with interleukin-2
30. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: A 20 year follow up study
31. Infections in organ transplant recipients
32. Increased incidence of lymphoproliferative disorders after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients
33. Skin cancer after renal transplantation: The causal role of azathioprine
34. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years
35. Infectious complications in renal transplant recipients: A 10-year review of cyclosporine-based immunosuppression
36. Drugs acting on the immune system
37. Clinical toxicity of interleukin-2
38. Clinical toxicity of the interferons
39. Immune-mediated side-effects of cytokines in humans
40. Clinical toxicity of cytokines used as haemopoietic growth factors
41. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation
42. Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: Case report and review
43. Invasive pulmonary aspergillosis associated with infliximab therapy
44. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients